The antimetabolite 6-thioguanine (6-TG) is utilized in the management of acute myelogenous leukemia (AML). Angiogenesis is a possible therapeutic target in hematologic tumors. Thus, we addressed the possibility that 6-TG may also act as an antiangiogenic molecule. 6-TG inhibited endothelial cell proliferation triggered by fibroblast growth factor-2 (FGF2) and vascular endothelial growth factor (VEGF) and delayed the repair of a mechanically wounded endothelial cell monolayer. Also, 6-TG inhibited sprouting within fibrin gel, morphogenesis on Matrigel, and collagen gel invasion by endothelial cells. 2-Aminopurine was ineffective. In vivo, 6-TG inhibited basal, VEGFinduced, and FGF2-induced vascularization in the chick embryo chorioallantoic membrane and prevented neovascularization triggered by leukemia LIK cells or their conditioned medium. Finally, bone marrow vascularization in AML patients was decreased to control values in the early remission phase and persisted unvaried after 8-12 months of maintenance therapy with 6-TG. Thus, 6-TG inhibits different steps of the angiogenesis process in vitro and exerts a potent anti-angiogenic activity in vivo. Its anti-angiogenic activity, together with its antimetabolite activity towards tumor cells, may contribute to its action during maintenance therapy in AML. These results suggest a new rationale for the use of purine analogs in the management of AML.
Introduction
In the adult, the proliferation rate of endothelial cells is very low compared to many other cell types in the body. Uncontrolled endothelial cell proliferation is observed in tumor neovascularization, angioproliferative diseases like Kaposi's sarcoma, and angiogenesis-dependent diseases like rheumatoid arthritis, psoriasis, and a number of eye diseases. 1 Various angiogenesis inhibitors have been developed so far, their efficacy has been evaluated in different in vitro and in vivo assays, 2 and their clinical evaluation in cancer patients is in progress (for further information about angiogenesis inhibitors in clinical trials see the NCI web site: http://cancertrials.nci.nih.gov). Recently, the hypothesis that anti-angiogenic compounds can be used in combination with cytotoxic drugs for tumor therapy has been advanced (see Ref.
3 and references therein). Also, chemotherapeutic agents have shown anti-angiogenic properties in vitro and in vivo, 4, 5 leading to the concept of anti-angiogenic scheduling of chemotherapy.
inhibit de novo purine synthesis and purine interconversion reactions and their metabolites can be incorporated into nucleic acids. 7 6-Thioguanine (6-TG) and 6-methylmercaptopurine riboside (6-MMPR) also alter membrane glycoprotein synthesis. 8 Purine analogs can act as protein kinase inhibitors, 6-MMPR showing a high potency and selectivity for nerve growth factor-activated protein kinase N. 9 2-Aminopurine (2-AP) inhibits proto-oncogene and interferon gene transcription. 10 Combination chemotherapy regimens for the management of solid tumors have been proposed in which purine analogs are administered in association with cytotoxic drugs. 11, 12 At present, the purine analog 6-TG is used in the management of acute myelogenous leukemia (AML) both in remission induction and in maintenance therapy. 7 An increasing body of evidence points to a role for bone marrow angiogenesis in hematologic tumors. [13] [14] [15] For instance, bone marrow vascularization is increased in patients with AML. [15] [16] [17] Also, AML cells produce angiogenesis factors, including fibroblast growth factor-2 (FGF2) and vascular endothelial growth factor (VEGF), 15 whose levels are an independent predictor of outcome. 18 Recently, we demonstrated that the purine analog 6-MMPR modulates the angiogenic activity of FGF2 in vitro and affects blood vessel formation in vivo. 19 Also, continuous systemic administration of 6-mercaptopurine ribose phosphate inhibits angiogenesis in the rabbit cornea. 5 In contrast, 6-methylmercaptopurine, 2-AP, and adenine are devoid of anti-angiogenic activity, 19 thus indicating that subtle structural differences may determine the ability of purine analogs to affect neovascularization. On this basis, we addressed the possibility that 6-TG may act as an anti-angiogenic molecule, this activity contributing to its efficacy in AML therapy.
6-TG was evaluated for the capacity to affect various steps of the angiogenesis process (ie cell proliferation, motility, endothelial cell sprouting, collagen invasion, and formation of capillary-like structures) induced by FGF2 and/or VEGF in cultured endothelial cells of different origin. The in vitro observations were compared to the effect of 6-TG on in vivo neovascularization in the chick embryo chorioallantoic membrane (CAM) under basal conditions or during neovascularization induced by FGF2 or VEGF or by human leukemia LIK cells grafted on to the CAM. Finally, we evaluated bone marrow vascularization in AML patients given maintenance therapy with 6-TG. The results demonstrate that 6-TG inhibits different steps of the angiogenesis process in vitro and exerts a potent anti-angiogenic activity in the CAM. Its anti-angiogenic capacity, together with its antimetabolite activity, may contribute to its action during maintenance therapy in AML patients. 21 They express high levels of FGF2 and form highly vascularized tumors in nude mice.
Cell cultures
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FGF2-T-MAE cells were grown in DMEM supplemented with 4 mM glutamine (Gibco) and 10% FCS. Bovine aortic endothelial (BAE) cells (provided by A Vecchi, Istituto Mario Negri, Milan, Italy) were cultured in MEM-Eagle's medium supplemented with 10% FCS, 2% essential amino acids and 2% vitamins. Cultures were used between the 6th and the 10th cell passage. LIK cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and grown in RPMI-1640 medium (Gibco) supplemented with 10% heat inactivated FCS and 1% glutamine.
Cell proliferation assays
GM 7373 cells were seeded at 70 000 cells/cm 2 . After overnight incubation, cells were incubated for 24 h in fresh medium containing 0.4% FCS and 10 ng/ml FGF2 in the presence of increasing concentrations of purine analogs. At the end of the incubation, cells were trypsinized and counted in a Burker chamber. Under these experimental conditions, cultures incubated in 0.4% FCS or 0.4% FCS plus FGF2 undergo 0.1-0.2 and 0.7-0.8 cell population doublings, respectively. 22 MAE cells were seeded at 25 000 cells/cm 2 . After overnight incubation, cells were starved for 48 h in fresh medium containing 0.5% FCS. Then, cells were treated with 30 ng/ml FGF2 in the absence or presence of purine analogs. After 18 h, cells were incubated with 3 H-thymidine (1 Ci/ml) for a further 6 h and radioactivity incorporated into the TCA-insoluble material was measured. FGF2-T-MAE cells (75 000/cm 2 ) were incubated with complete medium in the absence or in the presence of purine analogs. After 24 h, cells were trypsinized and counted in a Burker chamber.
Leukemia
Wounding of endothelial cell monolayers
Endothelial cells were allowed to reach confluence. Then, wounds were created in the cell monolayer with a 1.0-mm wide rubber policeman. Cultured medium and detached cells were removed and monolayers were incubated in fresh medium added with 10% FCS and the purine analog under test. 20 The number of cells migrating into the wound was measured by computerized image analysis 36-48 h after wounding.
Preparation of three-dimensional gels
Fibrin gels were prepared as described, 23 with minor modifications. Briefly, MBE or FGF2-T-MAE cell aggregates, prepared on agarose-coated plates exactly as described, 24 were seeded on to fibrin-coated 24-well plates. Immediately after seeding, 500 l of calcium-free medium containing fibrinogen Leukemia (2.5 mg/ml) and thrombin (250 mU/ml) were added to each well and allowed to gel for 5 min at 37°C. Then, 500 l of culture medium were added on the top of the gel. Culture medium was renewed every 48 h. When present FGF2 and purine analogs were added to both fibrin gel and cell culture medium at the indicated concentrations. In all the experiments the fibrinolytic inhibitor trasylol was added to the gel and to the culture medium at 200 KIU/ml to prevent the dissolution of the substrate. 23 Formation of radially growing cell sprouts was observed during the next 2-5 days.
Matrigel (10 mg/ml; Becton Dickinson, Milan, Italy) was used to coat 48-well plates at 4°C (150 l/well). After gelification at 37°C, FGF2-T-MAE cells were seeded on to Matrigel-coated dishes at 75 000 cells/cm 2 in the absence or in the presence of purine analogs. Newly formed endothelial cell 'cords' and 'tubes' were photographed using an inverted phase contrast photomicroscope.
For the preparation of three-dimensional gels of reconstituted collagen fibrils, 7 volumes of 1.5 mg/ml rat tail tendon type I collagen (Boehringer Mannheim Italia, Milan, Italy) dissolved in 0.1% acetic acid were mixed on ice with 2 volumes of 5× concentrated medium containing NaHCO 3 and 1 volume of 250 mM Hepes. The pH of the mixture was balanced by alkaline solution containing 1.0 N NaOH and 22 mg/ml NaHCO 3 . The mixture was allowed to solidify in 24-well plates (0.4 ml/well) at 37°C. Then, BAE cells were seeded on the top of collagen gel and allowed to reach confluence. Cell cultures were then treated with FGF2 plus VEGF 165 (both at 30 ng/ml) in the absence or in the presence of purine analogs. After 24 h, cells were photographed using an inverted phase contrast photomicroscope and endothelial cells invading the gel, in a plane of focus beneath the cell monolayer surface, were quantified by computerized analysis of the digitalized images. 
Chorioallantoic membrane (CAM) assay
Fertilized White Leghorn chicken eggs were incubated under conditions of constant humidity at a temperature of 37°C. On the third day, a square window was opened in the shell after removal of 2-3 ml of albumen to detach the shell from the developing CAM. The window was sealed with a glass of the same size and the eggs were returned to the incubator.
In a first set of experiments, 10 l-methylcellulose disks, containing 5 nmols of 6-TG, 2-AP, or 400 ng of affinity-purified anti-FGF2 antibody (provided by DB Rifkin, New York University Medical Center, New York, NY, USA), were implanted on the top of chick embryo CAM at day 8. At day 12, CAM were processed for light microscopy and the angiogenic response was assessed by a planimetric method of 'point counting'. 25 Briefly, every third section within 60 serial slides from an individual specimen was analyzed by a 144-point mesh inserted in the eyepiece of a Leitz-Dialux 20 photomicroscope. Six randomly chosen microscopic fields of each section were evaluated at ×160 magnification for the total number of the intersection points which were occupied by vessels transversally cut (diameter ranging from 3 to 10 m). Mean values ± standard deviation for vessel counts were determined for each analysis. The vascular density was indicated by the final mean number of the occupied intersection points as percent of the total number of intersection points. The statistical significance of differences among the mean values of the intersection points in the experimental series was determined by Student's t-test for unpaired data. The planimetric method of 'point counting' was also utilized for the quantitation of fibroblast density within CAM mesoderm.
In a second set of experiments, gelatin sponges (Gelfoam Upjohn Company, Kalamazoo, MI, USA) were cut to a size of 1 mm 3 and placed on top of the CAM at day 8, under sterile conditions. 26 The sponges were then adsorbed, in the absence or in the presence of 6-TG (5-50 nmols/sponge), with PBS, FGF2, or VEGF 165 (both at 1 g/sponge), 1 l of LIK cell suspension (20 000 cells/sponge), or 3 l of their five-fold concentrated conditioned medium prepared as described. 27 At day 12, CAMs were photographed in ovo with a stereomicroscope equipped with a Camera System MC 63 (Zeiss, Oberkochen, Germany). Blood vessels entering the sponges within the focal plane of the CAM were counted by two observers in a double-bind fashion at ×50 magnification. 28 
Serial evaluation of bone marrow neovascularization in AML patients
Bone marrow biopsies from five patients with AML (males/females, 5/2; median age, 65 years) were studied at diagnosis, after remission induction therapy (in months 1-3) and during remission maintenance therapy (in months [8] [9] [10] [11] [12] . Diagnosis and classification (three patients: M2; one patient: M3; one patient; M5) were done according to the criteria of the French-American-British (FAB) Cooperative Group. 29 Remission induction therapy consisted of cytosine arabinoside (100 mg/m 2 daily for 7 days), daunorubicin (45 mg/m 2 daily for 3 days), and etoposide (75 mg/m 2 daily for 7 days). After remission, patients were given maintenance therapy with 6-TG (Tabloid brand Thioguanine, 2 mg/kg body weight daily Leukemia or every other day). Control subjects were eight patients with anemia due to iron or vitamin B 12 deficiencies (males/females, 5/3; median age, 48 years). The study protocol was approved by the Research Ethics Committee of the University of Bari and informed consent was obtained from all patients. Biopsies were studied for microvessel density as described.
14 Briefly, 6-m deparaffinized and hydrated sections were sequentially incubated with a monoclonal (murine, IgG1) antibody to the endothelial cell marker factor VIII-related antigen (FVIII-
The area occupied by microvessels, or 'microvessel area', was calculated by using the planimetric method of 'point counting', according to which the area equalled the sum of points (129 m 2 per point) that hit microvessels. The microvessel area was normalized to the cellular area (grid area minus dense connective tissue, bone lamellae, fat, necrosis and hemorrhagic areas) by computerized image analysis.
Results
Effect of 6-TG on cultured endothelial cells
To evaluate a possible angiosuppressive activity of 6-TG, the drug and its analog 2-AP, here used as a negative control, 19 were tested for the capacity to inhibit cell proliferation in endothelial GM 7373 cells treated with FGF2 or VEGF. As shown in Figure 1a , 6-TG inhibits cell proliferation triggered by the two angiogenic growth factors with a similar potency. Also, 6-TG inhibits FGF2-induced proliferation in MAE cells and in FGF2-overexpressing endothelial FGF2-T-MAE cells in the M range of concentrations (Figure 1c, d ). 2-AP was instead ineffective in all the endothelial cell types tested. Also, when FGF2-treated GM 7373 cells were incubated for 3 days with 30 M 6-TG and then the culture medium was changed to fresh medium with no addition, the number of 6-TG-treated cells remained unchanged for the next 5 days (Figure 1b) . It must be pointed out, however, that cell viability was still higher than 95% after 8 days of treatment with 6-TG as evaluated by trypan blue staining of trypsinized cells (data not shown). Taken together, these data indicate that 6-TG exerts a potent cytostatic effect on endothelial cells.
6-TG also significantly affected the capacity of GM 7373 cells to repair a mechanically wounded cell monolayer. A complete repair was observed 2 days after wounding in control cultures (Figure 2a ) and in cultures treated with 100 M 2-AP (Figure 2b) , whereas a significant reduction in cell migration occurred in cultures treated with 100 M 6-TG (Figure 2c) . Similarly, 10 M and 100 M 6-TG inhibited the repair of mechanically wounded monolayers of MAE cells (Figure 2d) .
The capacity of 6-TG to affect different steps of the angiogenesis process was investigated further by the in vitro sprout formation assay. 23 In this assay, endothelial cell aggregates are embedded into the fibrin gel in the presence of angiogenic stimuli and the formation of radially growing endothelial sprouts follows. Accordingly, MBE cell aggregates invade the gel and form solid sprouts after 2-3 days in culture when incubated in the presence of 30 ng/ml FGF2. 6-TG (30 M) fully prevented sprout formation whereas 2-AP was ineffective (Figure 3a-c) .
In vitro, the culture of different endothelial cell types on Matrigel, a laminin-rich gelled basement membrane matrix, results in the formation of vascular tubes, a phenomenon known as 'spontaneous angiogenesis'. 30 Previous observations in our laboratory had shown that FGF2-T-MAE cells invade 3D fibrin gel and undergo morphogenesis on Matrigel. 31 As shown in Figure 3d -i, 6-TG was able to inhibit fibrin invasion and vascular tube formation on Matrigel by FGF2-T-MAE cells when tested at 30 M. Again, 2-AP was ineffective.
Finally, 6-TG suppressed the ability of BAE cells to invade a 3D collagen gel when stimulated by FGF plus VEGF. No activity was instead exerted by 2-AP (Figure 4) .
In conclusion, 6-TG inhibits the in vitro different steps of the angiogenesis process including endothelial cell proliferation, migration, sprout formation, invasion, and morphogenesis.
Effect of 6-TG on the vascularization of the chick embryo CAM
On the basis of the in vitro observations, 6-TG was evaluated for the capacity to affect the basal growth of new blood vessels in vivo in the chick embryo CAM. 25 The macroscopic vascular pattern of CAMs exposed to 5 nmols 2-AP delivered from day 8 to day 12 of development by a methylcellulose disk implant was indistinguishable from that of control embryos (Figure 5a,  b) . In contrast, an avascular zone free of blood vessels was evidenced beneath the implants containing 5 nmols of 6-TG (Figure 5c ), similar to that observed in embryos treated with neutralizing anti-FGF2 antibody (not shown, see Ref. 13 ). His- tological observation of CAM sections at day 12 showed that the CAM of control embryos was formed by flat chorion and allantoic epithelia with capillary blood vessels located at the base of the chorion and by the mesoderm containing large arteries and veins, fibroblasts, and few leukocytes (Figure 5d ). Normally developed blood vessels were also detectable in the CAM of 2-AP-treated embryos (Figure 5e ). No blood vessels were instead recognizable beneath the chorion and in the mesoderm of CAMs treated with 6-TG or anti-FGF2 antibody (Figure 5f, g ). Quantitation of blood vessel density by a planimetric method of 'point counting' confirmed the morphological observations and point to an anti-angiogenic effect for 6-TG in vivo (Table 1) . Interestingly, at variance with anti-FGF2 antibody, 6-TG administration did not affect fibroblast density Leukemia in CAM mesoderm (Table 1) , ruling out a possible non-specific cytotoxic effect of this compound. In a second set of experiments, 6-TG delivered via a gelatin sponge implant 26 inhibited both basal, FGF2-induced, and VEGF-induced CAM neovascularization with similar dose responses (Figure 6a) . To assess whether 6-TG was also able to inhibit hematologic tumor-induced angiogenesis, 6-TG was evaluated for the capacity to affect neovascularization triggered by leukemia LIK cells when grafted on to the CAM at day 8 via the gelatin sponge implant. In agreement with previous observations, 27 LIK cells implanted on to the CAM induced a potent angiogenic response that was significantly reduced by 6-TG given at 25 nmols/implant (Figure 6b) . A similar inhibitory effect was observed when angiogenesis was induced by the conditioned medium of LIK cells (Figure 6b ).
Figure 6
Effect of 6-TG on FGF2, VECF, and LIK cell-induced CAM vascularization. One mm 3 gelatin sponges were placed on top of the CAM at day 8 under sterile conditions. The sponges were then adsorbed with PBS, FGF2, or VEGF 165 (both at 1 g/sponge), 1 l of LIK cell suspension (20 000 cells/sponge) or PBS, or 3 l of their fivefold concentrated conditioned medium (LIK CM) or of control five-fold concentrated fresh medium (FM) in the absence or in the presence of 6-TG (5-50 nmols/sponge). At day 12, blood vessels entering the sponges within the focal plane of the CAM were counted by two observers in a double-bind fashion at ×50 magnification. Each point is the mean ± s.d. of 10 embryos. **Statistically different from 6-TGuntreated embryos (P Ͻ 0.01 or better).
Effect of 6-TG on bone marrow vascularization in AML patients
Five AML patients were assessed for bone marrow angiogenesis at diagnosis. Then, they underwent remission induction therapy for 7 days followed by maintenance therapy with 6-TG (2 mg/kg body weight daily or every other day). Bone marrow angiogenesis was assessed again in the same patients both in the early (months 1-3) and in the late (months 8-12) phases of maintenance therapy when all patients were in complete remission. In agreement with previous observations, [15] [16] [17] AML patients were characterized by intense bone marrow angiogenesis when compared to control patients ( Figure 7 and Table  2 ). However, the FVIII-RA-positive microvessel area was markedly decreased in the early remission phase and persisted unvaried after 8 to 12 months of maintenance therapy with 6-TG. In addition, changes in microvessel morphology were observed in the bone marrow of all AML patients during therapy. Indeed, blood vessels at diagnosis were thin, winding, often without evident lumen, with single spread endothelial cells and small endothelial sprouts (Figure 7a, d) . In contrast, vessels were straight, small, and no endothelial sprouts were evident both in the early (Figure 7b , e) and in the late ( Figure  7c , f) remission phase.
Discussion
New blood vessel formation is a multi-step process that begins with the degradation of the basement membrane by activated endothelial cells that will migrate and proliferate, leading to the formation of solid endothelial cell sprouts into the stromal space. Then, vascular loops are formed and capillary tubes develop with formation of tight junctions and deposition of new basement membrane. 32 Each step of this process represents a potential target for the inhibitory action of angiostatic molecules. 2 In the present paper we describe the anti-angiogenic activity of the purine analog 6-TG. Our results indicate that 6-TG affects various cell proliferation-independent aspects of the angiogenesis process (ie endothelial cell motility, sprout formation, collagen gel invasion, and morphogenesis) at concentrations that are cytostatic but not cytotoxic for endothelial cells. This suggests that 6-TG acts as an angiostatic molecule on multiple targets of the angiogenic process. This hypothesis is supported by the observation that the anti-angiogenic activity exerted in vivo by this purine analog on the physiological blood vessel development of the chick embryo CAM is not the mere consequence of a generic inhibitory action on cell proliferation, as demonstrated by the lack of effect of 6-TG administration on fibroblast density of the CAM mesoderm.
6-TG is used in the management of AML both in remission induction and in maintenance therapy. 7 Previous observations have shown that various leukemia cell lines produce and release significant amounts of angiogenic growth factors. 16, 27 Accordingly, they trigger an angiogenic response in different in vivo animal models, including the CAM assay. 27 Here, 6-TG inhibits new blood vessel formation induced by leukemia LIK cells grafted on to the CAM. This appears to be due to a direct angiosuppressive effect rather than to an indirect activity of the drug on LIK cells. Indeed, 6-TG was also able to inhibit neovascularization triggered by the conditioned medium of LIK cells or by recombinant FGF2 or VEGF.
Purine analogs can act as protein kinase inhibitors 9 and modulate gene expression in different experimental systems, 10, 11 thus indicating that this class of compounds can interfere with intracellular signaling and growth factor activities. 19, 33, 34 Moreover, 6-TG and 6-MMPR alter membrane glycoprotein synthesis. 8 Thus, besides the well characterized effects of purine analogs as antimetabolic drugs able to inhibit de novo purine synthesis and purine interconversion reactions, 7 various mechanisms of action may be responsible for the anti-angiogenic activity of 6-TG. Further experiments are required to clarify this point. Also, the chemical structure of purine analogs appears to be of importance for their capacity to act as angiogenesis inhibitors. Indeed, 6-TG (present work), 6-MMPR, 19 and 6-mercaptopurine ribose phosphate 5 are potent angiostatic compounds whereas the structurally related 2-AP, 6-methylmercaptopurine, and adenine are ineffective. 13 A detailed analysis on a larger number of compounds will be required to better define the structure-function relationship of angiostatic purine analogs.
Compelling experimental evidence indicates that bone mar-
Figure 7
Bone marrow vascularization in AML patients given 6-TG during maintenance therapy. Factor VIII-RA immunostaining of bone marrow biopsies from two representative AML patients who were treated with remission induction therapy for 7 days, attained complete remission, and were then given maintenance therapy with 6-TG. Numerous microvessels were detectable at diagnosis in both patients (a, d). In the remission phase (b, month 2; e, month 3) vessels were rare (arrowheads). A very limited vascularization was observed also during the maintenance therapy with 6-TG (c, month 8; f, month 12). Note several strongly stained megakaryocytes as internal positive controls (b, c, e and f). Bar = 60 m (a-f). Bone marrow biopsies from five AML patients were studied for microvessel density at diagnosis, after remission induction therapy (months 1-3), and during maintenance therapy with 6-TG (months [8] [9] [10] [11] [12] . Control subjects (n = 8) were patients with anemia due to iron or vitamin B 12 deficiencies. Microvessel area was calculated by using the planimetric method of 'point counting' and was normalized to the cellular area by using a computerized image analysis software. row angiogenesis plays an important role in hematologic tumors. [13] [14] [15] Here, we have shown that bone marrow vascularization is significantly increased in AML patients at diagnosis in respect to control patients. This is in keeping with previous findings on bone marrow vascularization in larger cohorts of AML patients [15] [16] [17] and with the observation that the plasma levels of various angiogenic growth factors are increased in these patients. 15, 18 Previous observations have also shown that induction chemotherapy using the TAD protocol (standard-dose cytarabine, daunorubicin and 6-TG) 35 causes a significant decrease of bone marrow vascularization in AML patients without residual leukemic blast infiltration but not in patients with residual disease. 17 In our patients, bone marrow vascularization was reduced to control values after remission induction by cytosine arabinoside, daunorubicin and etoposide treatment, and remained unvaried during maintenance therapy with 6-TG (up to 12 months after remission). Even though these data do not formally prove that 6-TG acts directly on bone marrow endothelium in AML patients, the in vitro and in vivo evidence about its anti-angiogenic activity, including its capacity to inhibit CAM neovascularization induced by leukemia LIK cells and their conditioned medium, strongly supports the hypothesis that the angiostatic capacity of 6-TG, together with its antimetabolite activity, may contribute to its action in AML therapy.
Leukemic cells release endothelial growth factors. 16, 27, 36, 37 In turn, activated endothelial cells release cytokines that stimulate leukemia cell growth. 38 Our data suggest that 6-TG may interrupt this reciprocal loop of stimulation between leukemic and endothelial cells by acting on both cell types. Interestingly, a similar mechanism of action has been hypothesized for arsenic trioxide and vinblastine in the therapy of hematologic tumors. 39, 40 The combined therapeutic approach targeting both tumor cells (by conventional cytotoxic agents) and endothelial cells (by angiogenesis inhibitors) may lead to synergistic antitumor effects. 3, 5 The anti-angiogenic action of cytostatic chemotherapy may therefore contribute to the eradication of leukemic cells.
In conclusion, our data demonstrate that 6-TG exerts a potent anti-angiogenic activity in vitro and in vivo thus suggesting a new rationale for its use in the management of AML in remission induction and in maintenance therapy.
